Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium inwardly rectifying channel subfamily J member 4 (KCNJ4), also known as Kir2.3, is an integral membrane protein that forms a channel allowing potassium ions to flow into the cell more easily than out, thereby playing a fundamental role in maintaining the resting membrane potential [UniProt P48050]. It is widely expressed in the human body, with high levels found in the heart, brain, and skeletal muscle, where it regulates cellular excitability and the duration of action potentials [NCBI Gene 3761]. In the heart, Kir2.3 is a key component of the inward rectifier current (IK1), and its dysregulation is closely linked to the pathogenesis of atrial fibrillation and other cardiac arrhythmias [PubMed 15618241]. Within the central nervous system, the channel is often localized to the postsynaptic density of excitatory synapses, where it interacts with PDZ-domain proteins to influence synaptic transmission and neuronal firing [PubMed 10433264]. While many existing drugs that interact with Kir2.3, such as quinidine and chloroquine, are non-selective, the channel remains a significant target for the development of novel anti-arrhythmic and neuroprotective therapies [PubMed 11830606]. Understanding the structural and functional nuances of Kir2.3 is essential for designing drugs that can precisely modulate its activity without causing adverse off-target effects on related potassium channels.
Inhibition of the inward rectifier potassium current (IK1) to modulate membrane potential and cellular excitability.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium inwardly rectifying channel subfamily J member 4 (KCNJ4) (KCNJ4).